Abstract

Fully targeted mRNA therapeutics necessitate simultaneous organ-specific accumulation and effective translation. Despite some progress, delivery systems are still unable to fully achieve this. Here, we reformulate lipid nanoparticles (LNPs) through adjustments in lipid material structures and compositions to systematically achieve the pulmonary and hepatic (respectively) targeted mRNA distribution and expression. A combinatorial library of degradable-core based ionizable cationic lipids is designed, following by optimisation of LNP compositions. Contrary to current LNP paradigms, our findings demonstrate that cholesterol and phospholipid are dispensable for LNP functionality. Specifically, cholesterol-removal addresses the persistent challenge of preventing nanoparticle accumulation in hepatic tissues. By modulating and simplifying intrinsic LNP components, concurrent mRNA accumulation and translation is achieved in the lung and liver, respectively. This targeting strategy is applicable to existing LNP systems with potential to expand the progress of precise mRNA therapy for diverse diseases.

Targeted delivery of mRNA using lipid nanoparticles is currently a challenge. Here, the authors examine the composition of LNPs and report changes to the standard formulation can address issues with liver accumulation and allow for increased tissue specific targeting.

Details

Title
Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation
Author
Su, Kexin 1   VIAFID ORCID Logo  ; Shi, Lu 2 ; Sheng, Tao 1 ; Yan, Xinxin 1 ; Lin, Lixin 1 ; Meng, Chaoyang 3 ; Wu, Shiqi 2 ; Chen, Yuxuan 1   VIAFID ORCID Logo  ; Zhang, Yao 1 ; Wang, Chaorong 1 ; Wang, Zichuan 1 ; Qiu, Junjie 1 ; Zhao, Jiahui 1 ; Xu, Tengfei 1 ; Ping, Yuan 2   VIAFID ORCID Logo  ; Gu, Zhen 2   VIAFID ORCID Logo  ; Liu, Shuai 4   VIAFID ORCID Logo 

 Zhejiang University, State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Zhejiang University, State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, Liangzhu Laboratory, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Zhejiang University, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Zhejiang University, State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, Liangzhu Laboratory, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, Eye Center, The Second Affiliated Hospital, School of Medicine, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
Pages
5659
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3076104631
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.